Skip to search formSkip to main contentSkip to account menu

CB-839

Known as: Glutaminase Inhibitor CB-839 
An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzeneacetamidesThiadiazoles
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.
574 Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) are approved in RAS WT mCRC; however… 
2019
2019
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematopoietic disease characterized by glutamine-dependent metabolism. A novel… 
2019
2019
Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).
7037 Background: Glutaminase (GLS) is an enzyme that catalyzes conversion of glutamine to glutamate, providing key metabolic fuel… 
2019
2019
Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial…
Background: CB-839 is an investigational first-in-class, potent, oral inhibitor of glutaminase (GLS), a mitochondrial enzyme that… 
2018
2018
Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
Background: CB-839 is a first-in-class oral highly selective inhibitor of glutaminase (GLS), a mitochondrial enzyme that plays a… 
2018
2018
Abstract 3509: The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models
Many tumor cells utilize the amino acid glutamine to meet the elevated bioenergetic and biosynthetic demands of rapid cell growth… 
2018
2018
A usable model of “decathlon winner” cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence
We previously described a strategy for selecting highly adaptable rare triple-negative breast cancer (TNBC) cells based on their… 
2015
2015
Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma
Introduction Glutaminase is a mitochondrial enzyme that converts glutamine to glutamate to support several metabolic processes… 
2014
2014
Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models
Many hematological tumor cells are dependent on glutamine for growth and survival. Glutamine is the most abundant amino acid in… 
2014
2014
Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia
Inhibition of glutaminase (GLS), the principal enzyme in the glutamine utilization pathway that coverts glutamine (Gln) to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)